In patients with type 2 diabetes on metformin, efpeglenatide reduced HbA1c more than placebo over 16 weeks, with an overall least squares mean difference of -7.7 mmol/mol (-0.71%) from baseline to week 17 (all doses P<0.0001).
In plain wordsIn patients with diabetes on metformin, efpeglenatide reduced HbA1c more than placebo.
- Peptide
- Efpeglenatide
- Outcome
- DecreaseHbA1c change
- Study
n: not reported in source
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 8, 12 or 16 mg once monthly after titration · subcutaneous · 16 weeksAs given in this study (human).
Measurements
- Least squares mean difference in HbA1c reduction, efpeglenatide overall vs placebo
- −7.7 mmol/mol
- baseline to week 17
- Least squares mean difference in HbA1c reduction, efpeglenatide overall vs placebo
- −0.71%
- baseline to week 17
Source sentences
Overall, the least squares mean difference in HbA1c reductions between efpeglenatide and placebo was -7.7 mmol/mol (-0.71%; baseline to week 17).
3 context sentences(design, population, supporting numbers)
All efpeglenatide doses significantly reduced HbA1c versus placebo (P < 0.0001 for all).
In this phase 2, randomized, placebo-controlled, double-blind trial (NCT02081118), patients were randomized 1:1:1:1 to subcutaneous efpeglenatide (8, 12 or 16 mg once monthly; n = 158) or placebo (n = 51).
The 16-week treatment period included a 4-week titration phase with once-weekly efpeglenatide 4 mg, followed by one dose of efpeglenatide 8 mg once monthly and two doses of the assigned once-monthly dose.